Introduction
Thalassaemia refers to a group of inherited disorders of haemoglobin (Hb) synthesis and is the commonest monogenetic disease worldwide [1] . It is more common in certain ethnic groups. The estimated prevalence for different types of thalassaemia trait is up to 16% in Cypriot populations, 3-14% in Thai populations, 3-8% in Indian, Pakistani, Bangladedeshi and Chinese populations, 0.9% in black Caribbean and African populations, but is only 0.1% among northern Europeans [2, 3, 4 ] . However, due to immigration and intermarriage, this condition is an important concern in many parts of the world which have an immigrant population from the high-risk regions [5] . Hence, the understanding of this group of disorders and its relevance to pregnancy are very important to most obstetricians and midwives.
With the advent of molecular genetics, links between the different mutations and phenotypic diversity have been discovered [6 ] . Also, the availability of polymerase chain reaction (PCR) methods and arrays has allowed much quicker and more accurate prenatal diagnosis from chorionic villus sampling and amniocentesis [7,8 ,9 ] . In many parts of the world, screening and prenatal diagnosis programmes have been set up, leading to a dramatic reduction in the prevalence of this condition [10, 11] . However, even in developed countries with good antenatal care provision, service failure, such as a failure to recognize risk and to offer prenatal diagnosis, could still be demonstrated in over a quarter of affected pregnancies [12] . This article aims to provide an overview of antenatal screening and prenatal diagnosis of thalassaemia from the obstetrician's point of view. Non-invasive methods including ultrasound screening [13, 14 ] and the detection of fetal nucleic acids in maternal plasma reported recently [15, 16 ] will also be discussed.
Classification
The normal adult haemoglobin molecule, Hb A, consists of two alpha (a) and two beta (b) chains, which combine with the haem moiety. There are other kinds of haemoglobins and their compositions are summarized in Table 1 . The production of each type of globin chain is under separate genetic control. The genetic defect results in impaired production of a specific globin chain. The disorders are classified according to the particular globin chain that is ineffectively produced, which include a, b, g, d, db and egdb thalassaemias [1] . The a and b thalassaemias are the most important types. In addition to the disorders of thalassaemia, there might be structural haemoglobin variants such as Hb S, C and E. The most common types are Hb E-thalassaemia and sickle-cell (Hb S)-thalassaemia.
a Thalassaemia
Each normal individual has four a genes (aa/aa), two on each chromosome 16. a Thalassaemia results from mutations affecting one or more of the a genes. The mutation may be the result of a gene deletion or, less commonly, it may be a non-deletional point mutation [1, 17] . The patterns of mutation are ethnically specific [18 ] .
Individuals with one a gene deletion (-a/aa), which is termed a þ thalassaemia or heterozygous a-thal-2, are silent carriers. The haematological investigation is normal except for occasional low red cell indices [19] . The haemoglobin electrophoresis is usually normal. This condition is particularly common in parts of Africa, the Mediterranean countries, southeast Asia and the Pacific islands [18 ] .
Mutations affecting two a genes cause a condition called a thalassaemia trait (minor), which is characterized by mild anaemia and low red cell indices. The mean cell haemoglobin (MCH) and the mean corpuscular volume (MCV) are typically below 27 pg and 78 fl, respectively [18 ] . The Hb A2 is normal. Occasional Hb H granules may exist on a haemoglobin pattern but not in every case. Affected individuals are clinically asymptomatic. There are two forms of genotype. Mutation of both a genes on the same chromosome (-/aa) is called a 0 thalassaemia or heterozygous a-thal-1. This is particularly prevalent in the southern provinces of China, southeast Asia, the Middle East and the Mediterranean countries [4 ,20,21] . The other form of genotype, the homozygous a-thal-2 (-a/-a), is more prevalent among the southeast Indians, Africans and Afro-Caribbeans, and will not give rise to offspring with a thalassaemia major [22] .
Compound heterozygotes for a 0 and a þ thalassaemia result in Hb H disease (-/-a). These individuals have mild to moderate anaemia, splenomegaly and abnormal red cell indices [17, 23 ] . Hb H is a homotetramer formed by the excessive b chains. Patients with the nondeletional type of Hb H disease have more severe anaemia than those with the deletional type, and are more likely to require transfusion [17, 23 ] .
The homozygous state for a 0 thalassaemia (-/-) results in haemoglobin Bart's disease, which is characterized by early onset of hydrops fetalis, intra-uterine or early neonatal death, and a higher risk of maternal pre-eclampsia [24] [25] [26] . The name 'haemoglobin Bart's' refers to the tetramers of the excessive g chains, formed as a result of the complete absence of a chains.
b Thalassaemia b Globin chain synthesis is determined by two b genes, one on each chromosome 11. Over 200 different mutations of the b globin genes have been reported, resulting in either no or impaired production of b chains (b 0 and b þ thalassaemia, respectively) [6 ] . b Thalassaemia is prevalent in the Mediterranean countries, North Africa, the Middle East, India, and southeast Asia [27] .
Individuals with b thalassaemia minor are heterozygous for a b-globin mutation. They have mild or no anaemia and are usually asymptomatic clinically. The peripheral smear shows hypochromia and microcytosis. Unless there is concomitant a or d thalassaemia or iron deficiency, there are elevated levels of Hb A2 and Hb F on a haemoglobin pattern.
b Thalassaemia major or Cooley's anaemia results from homozygous b 0 thalassaemia or compound heterozygosity for b 0 and b þ thalassaemia. The former is the more severe form, with no production of b globin chains. Individuals suffering from thalassaemia major usually present at less than 1 year of age with severe anaemia. They are at risks of complications such as hepatosplenomegaly, bone deformities and growth delay. Regular transfusion and iron chelation therapy are required to sustain life. Bone-marrow transplantation has an increasingly high success rate [28] . Haemoglobin E/b thalassaemia Hb E is an abnormal haemoglobin with lysine substituted for glutamic acid at position 26 of the b chain; it is seen most often in southeast Asia, especially Thailand [29] .
Compound heterozygotes for Hb E and a b thalassaemia gene (Hb E/b thalassaemia) show a diversity of clinical severity ranging from b thalassaemia intermedia to b thalassaemia major [29] .
db Thalassaemia (haemoglobin Lepore)
This form of thalassaemia results from a misalignment in the d-b genes during meiosis, leading to the production of fused db genes. The process of transcription becomes ineffective, resulting in limited production of fused db chains. The haemoglobin variant produced is termed 'Hb Lepore', which consists of two a and two fused db chains. Homozygous individuals have 10% Hb Lepore, and very high Hb F levels but no Hb A or Hb A2, which results in thalassaemia major. Heterozygotes have varying amounts of Hb Lepore and Hb A and may have mild anaemia. Hb Lepore is more commonly seen in Greek and Italian populations [30] .
Sickle-cell/b thalassaemia
The co-inheritance of the sickle-cell gene and b-thalassaemia gene (Hb S/b thalassaemia) produces a disease that is similar to sickle-cell anaemia. The clinical phenotype depends on the type of b thalassaemia mutation (b 0 or b þ ) [31] . Subjects suffering from Hb S/b thalassaemia can experience vaso-occlusive crisis and other sickle-cell complications. Compared with patients with sickle-cell anaemia alone, patients with Hb S/b thalassaemia have a higher red cell count and higher levels of Hb A2, but lower MCV and MCH. The mean corpuscular haemoglobin concentration, total haemoglobin, Hb S, Hb A and Hb F were similar in the two groups [31] .
Antenatal screening
The majority of thalassaemias are autosomal recessive disorders and although dominant b thalassaemia exists, it is rare [32] . Hence, a couple with the same type of thalassemia trait have a 25% chance that the fetus is affected by thalassaemia major in each pregnancy. As the majority of pregnant women would not know whether they were thalassaemia carriers or not at antenatal booking, antenatal screening is very important to identify atrisk couples early in pregnancy so that timely genetic counselling can be offered.
A universal antenatal screening policy to suit all countries, however, cannot be found, given the heterogeneity of thalassaemias and the association with haemoglobin variants in different ethnic groups. Experience from universal screening in Cyprus, Greece and Sardinia has confirmed a significant reduction of thalassaemia major births by 50-97% [10] . In cities with a large immigrant population from all over the world, universal screening would be beneficial as the ethnic origin of the pregnancy might not be accurately obtained due to intermarriages between ethnic groups. A study conducted in London (UK) involving 2101 women has demonstrated the cost-effectiveness of a universal antenatal screening programme for thalassaemia [33] . However, if the programme is mainly for sickle-cell disease, it is only costeffective at a prevalence of above 2.5% of traits [33] .
The appropriate screening tests for haemoglobin variants, such as Hb S and Hb E, include haemoglobin electrophoresis and high-performance liquid chromatography. Such tests will not be discussed in detail here.
Screening for a and b thalassaemias
The appropriate measures to screen for a and b thalassaemias are MCH and MCV. Haemoglobin concentration is a poor screening tool for thalassaemia traits as it is most often within the normal range for pregnancy. Different cut-offs in MCV have been used in various screening programmes, ranging from 75 to 85 fl [18 ,34-36] . With MCH, 27 pg is the most acceptable cut-off [18 ,34] . It has been suggested that MCH is more reliable for thalassaemia screening than MCV because red cells stored at room temperature may swell over time [18 ] . The cut-off for MCH of 27 pg or MCV of 80 fl will screen out almost all of the thalassaemia carriers, especially those due to a 0 and b 0 thalassaemia mutations [18 ,37,38] . However, in very rare instances, a silent b thalassaemia mutation or a þ thalassaemia may present with a higher MCH or MCV value [18 ,19] . This needs to be taken into consideration in very high-risk pregnancies, particularly those with a positive family or past obstetric history.
When the MCH or MCV is low, tests for haemoglobin pattern and iron status should be arranged. Elevation of Hb A2 (>3.5%) and presence of Hb H inclusion bodies are diagnostic of b and a thalassaemia traits, respectively. It is important to realize that iron deficiency will suppress Hb A2 and, therefore, a normal Hb A2 in the presence of iron deficiency cannot exclude a co-existing b thalassaemia trait [39] . The haemoglobin pattern should be repeated after iron deficiency is corrected. In appropriate ethnic groups, for example Cypriots and Sardinians, the possibility of co-existing b and d thalassaemia should be suspected in women with low red cell indices but normal Hb A2 [22] . The diagnosis of a b thalassaemia trait can be confirmed with globin-chain synthesis or DNA studies. It is also important to remember that the absence of Hb H inclusion bodies cannot exclude a 0 thalassaemia.
Due to the limitations of haemoglobin pattern, it is advisable to check the MCH or MCV of the partner as a routine for pregnant women with low red cell indices, particularly among ethnic groups prevalent for a 0 thalassaemia. This is the current practice in Hong Kong. If the partner is screened negative, further work-up for gene analysis is not required. A partner who is screened positive should have the haemoglobin pattern and iron study. Molecular genetic testing is necessary for low MCH (or MCV) couples without iron deficiency despite normal haemoglobin pattern. In certain ethnic groups, such as Chinese, up to 7% of b thalassemia carriers have concomitant a thalassaemia trait [40] . Molecular genetic testing is therefore necessary for a-b couples to exclude co-inheritance of a 0 thalassaemia in the b thalassaemia carrier among these high-risk ethnic groups.
Management of at-risk couples
At-risk couples should be referred for detailed counselling on the options for prenatal diagnosis.
Invasive prenatal diagnosis
Traditionally, the couple are counselled for chorionic villus sampling or amniocentesis. It is important to emphasize that the wide variety of possible mutations are regionally specific, and the spectrum has been determined for most of the at-risk populations [18 ] . The precise details of ethnicity, relevant clinical history and parental blood samples should be submitted to the genetic laboratories prior to the submission of fetal samples so that the laboratories are better prepared [22] .
Ultrasound screening for a-thalassaemia couples
With the advent of ultrasound technique, an additional option is available for a-a (and a-ab) thalassaemia couples. As anaemia occurs very early in a fetus with haemoglobin Bart's disease, signs of hydrops fetalis and placentomegaly may be detected on ultrasound from the second trimester [24, 41] . Using a cut-off of two standard deviations above the mean placental thickness for gestational age, Ghosh et al. [24] have shown that the sensitivity and specificity of ultrasound for prediction of haemoglobin Bart's disease was 72% and 97%, respectively, before 12 weeks of gestation. At the same specificity, the sensitivity reached 100% after 18 weeks.
While overt features of hydrops fetalis are found in only one-third of affected pregnancies at 17-18 weeks [41] , fetal cardiomegaly, as shown by an increased cardiothoracic (C/T) ratio, turns out to be a sensitive marker [14 ,26] . Using the four-chamber view of the fetal heart, the cardiac diameter is measured at the level of the atrioventricular valves between the epicardial surfaces; the transverse thoracic diameter is measured in the same image and the C/T ratio can then be calculated [26] . In one study involving 484 at-risk pregnancies at 18-21 weeks of gestation, a ratio of >0.5 carries a sensitivity and specificity of 95.0% and 96.1%, respectively [14 ] .
The possibility of earlier detection at 12-14 weeks was evaluated by Lam et al. [13, 26] . From their initial data on 62 pregnancies assessed by transabdominal ultrasound, a C/T ratio of >0.5 provided a sensitivity and specificity of 65% and 100%, respectively [26] . The predictive value of the C/T ratio was superior to that obtained by measurement of the placental thickness. However, a C/T ratio was not obtainable at this early stage of gestation in 9.7% of the pregnancies. In this study, the sensitivity reached 100% at 17-18 weeks, at a specificity of 92% [26] . Subsequently, with the additional help of transvaginal ultrasound in difficult cases, the same group was able to detect all 43 affected pregnancies in 135 at-risk women at 12-14 weeks with no false positives [13] .
This finding is very promising as it shows that early diagnosis can be made by ultrasound, and thus the invasive prenatal diagnostic procedures, which carry a small but finite risk of miscarriage, can be avoided for unaffected pregnancies. However, although the idea of measuring the C/T ratio looks straightforward, expertise and good ultrasound machines are essential for accurate measurement. The excellent results of Lam et al. [13] from their subsequent study could be due to the additional use of transvaginal ultrasound, but might also be related to accumulated experience since the time of the initial study and the fact that the measurements were all obtained by only one of the authors. Provided expertise is available, it appears that serial ultrasound screening from 12-14 weeks using the C/T ratio is a reasonable option for a-thalassaemia couples.
Non-invasive prenatal diagnosis for b thalassaemia couples
Ultrasound screening has no value for the diagnosis of b thalassaemia major. However, the recent advances in analysis of circulating fetal nucleic acid in maternal plasma might provide a means for non-invasive prenatal screening in the future. Theoretically, it is entirely possible, as the manifestation of b thalassaemia major depends on the inheritance of both paternal and maternal mutations by the fetus. A small but measurable amount of fetal DNA circulates in the maternal plasma during pregnancy [42] , which can be checked for paternal mutation. Its absence in the maternal plasma would infer that the fetus has not inherited the mutant paternal allele and b thalassaemia major can be excluded. Invasive prenatal diagnosis is not required. However, if the paternal mutation is present in the maternal plasma, the fetus has a 50% chance of being affected, depending on whether he or she has inherited the maternal mutation as well.
In the latter case, invasive prenatal diagnosis will be useful. This approach was first shown to be possible by Chiu et al. [15] for one of the commonest genetic mutations in Hong Kong Chinese (codon 41/42 (-CTTT) mutation).
However, for this approach to be extended to other mutations in b thalassaemia, the system for identifying the fetal-specific marker in the maternal circulation has to be even more robust as the mutation often involves just a single-nucleotide difference [43] . These hurdles might be overcome with the use of advanced techniques such as the single allele base extension reaction (SABER), MassARRAY (MS) system (Sequenom Inc., San Diego, CA, USA), and the identification of a paternal specific single-nucleotide polymorphism close to the site of paternal mutation. In 12 at-risk pregnancies, these techniques were shown to provide accurate non-invasive prenatal screening for the four most common mutations in southeast Asia, which account for 90% of the cases of b thalassaemia in the area [16 ] . Apart from being robust, the approach also allows application to couples sharing the same mutation, which was previously thought to be impossible in maternal plasma-based prenatal diagnosis of autosomal recessive disease [15] . While these early results are promising, the techniques are very sophisticated and extremely costly at present. Validation by large-scale studies is required, but this should certainly provide an additional option for high-risk couples in the future.
Conclusion
Thalassaemia is the haematological disorder most commonly encountered in obstetric practice worldwide. For high-risk ethnic groups, antenatal screening and prenatal diagnosis help to identify affected pregnancies in utero so that informed choices can be made by the women.
In cities with a large immigrant population from all over the world, universal screening would be beneficial. Obstetricians should be familiar with the necessary investigations for identifying high-risk couples. At present, invasive prenatal diagnosis remains the gold standard for early diagnosis of thalassaemia major. However, with the development of ultrasound machines, clinical expertise and molecular genetics, we foresee a majority of at-risk couples being screened by non-invasive means in the future.
